An estimated 170,000 women in the United States are currently living with metastatic breast cancer, the stage where cancer has spread beyond the breast to distant organs like the bones, lungs, liver, or brain. That number is growing. Projections estimate it will reach roughly 246,000 by 2030, a 55% increase from 2015 levels, driven largely by an aging population and improving survival times that keep more people in the prevalent pool longer.
How Many People Are Diagnosed Each Year
Metastatic breast cancer arrives in two ways. Some people are diagnosed with it from the start, meaning the cancer has already spread by the time it’s first detected. This is called de novo metastatic breast cancer, and it accounts for about 3% to 6% of all new breast cancer diagnoses in high-income countries. With roughly 300,000 new breast cancer cases diagnosed annually in the U.S., that translates to somewhere between 9,000 and 18,000 women learning they have stage IV disease at their very first diagnosis.
The larger group, though, consists of people who were originally diagnosed with earlier-stage breast cancer and later experience a distant recurrence. Their cancer comes back in a new location, sometimes years or even decades after their initial treatment. These recurrent cases make up the majority of the metastatic breast cancer population.
When Recurrence Happens
The timing of recurrence depends heavily on the biology of the original tumor. Hormone receptor-negative cancers tend to recur early, typically within the first three years. HER2-positive breast cancer shows a recurrence peak around 20 months. Triple-negative breast cancer with rapidly dividing cells spikes sharply near 18 months. For all three of these subtypes, about 92% of recurrences happen within five years of the original diagnosis. After that, recurrence becomes rare.
Hormone receptor-positive cancers behave differently. Both luminal A and luminal B subtypes can recur at any point, including well beyond the five-year mark. In one study of patients who recurred after five years, 63% had luminal B disease. This is why people with hormone receptor-positive breast cancer often take hormone-blocking therapy for five to ten years and continue surveillance long after treatment ends.
Age at Diagnosis
The median age at metastatic breast cancer diagnosis is 54, but the range is wide. In a large international cohort of over 4,100 patients, 571 were 40 or younger at diagnosis, while 1,925 were between 55 and 75. Both the youngest and oldest patients face slightly worse outcomes compared to those diagnosed in middle age. Women diagnosed at 35 or younger and those over 65 both had roughly 20% to 30% higher risk of death compared to the 45-to-55 reference group, even after accounting for tumor characteristics.
Survival by Subtype and Spread
The five-year relative survival rate for distant-stage breast cancer is 33%, based on data from the National Cancer Institute’s SEER database covering diagnoses between 2015 and 2021. That single number, however, masks enormous variation depending on the cancer’s molecular subtype and where it spreads.
Hormone receptor-positive cancers (luminal A and luminal B) make up the largest share of metastatic cases, roughly 75% combined in registry data. These subtypes generally respond to hormone therapy and carry longer survival times. When hormone receptor-positive cancer spreads to bone, median survival often exceeds five years. Spread to the liver carries a median survival closer to four to five years.
HER2-positive metastatic breast cancer, about 12% of cases, has seen dramatic improvements thanks to targeted therapies. Median survival with bone metastases in one large registry was around 59 months, though liver and brain spread shortened that to 39 and 47 months respectively.
Triple-negative metastatic breast cancer, roughly 13% of cases, remains the most difficult to treat. Median survival with lung metastases was 34 months, and brain metastases dropped that to 29 months. These cancers lack the receptors that hormone therapy and HER2-targeted drugs act on, leaving fewer treatment options, though newer immunotherapy and antibody-drug combinations have begun to extend survival for some patients.
Metastatic Breast Cancer in Men
Men account for a small but real fraction of metastatic breast cancer. In one retrospective analysis, men made up about a quarter of all metastatic breast cancer patients at a single center, though this likely overrepresents male cases due to the study’s design. What stands out is that 39% of men with metastatic disease were diagnosed at stage IV from the start, compared to the 3% to 6% rate in women. This likely reflects lower awareness and later detection. Median survival from the point of metastasis was about 32 to 37 months for men, with a five-year survival rate near 22%. As with women, hormone receptor-positive disease carried better outcomes, while triple-negative disease was significantly worse.
The Global Picture
Breast cancer is the most commonly diagnosed cancer worldwide, with 2.3 million new cases and 670,000 deaths globally in 2022. The vast majority of those deaths are attributable to metastatic disease. In lower-income countries, a higher proportion of women are diagnosed at advanced stages due to limited screening and delayed access to care, meaning the de novo metastatic rate can climb well above the 3% to 6% seen in wealthier nations.
Why the Numbers Keep Rising
The growing prevalence of metastatic breast cancer is not primarily because more people are developing it. It’s because people are living longer with it. Better treatments, particularly for HER2-positive and hormone receptor-positive subtypes, have extended survival enough that the number of people living with the disease at any given time continues to climb. The aging of the U.S. population also plays a role, since breast cancer incidence increases with age. Interestingly, projections show a slight decline in metastatic cases among women 65 and older in coming years, as survival gains in that age group plateau. The overall increase is driven more by younger and middle-aged patients living longer with their disease.